Today News Journal
    What's Hot

    Statue of Adam Goodes’s ‘iconic’ war cry unveiled by AFL club Sydney Swans | Adam Goodes

    May 26, 2023

    Hull KR talking points as old habits creep in but panic stations miles away

    May 26, 2023

    Kate Middleton citrine cocktail ring: Jewel shows ‘independence’

    May 26, 2023
    Facebook Twitter Instagram
    Facebook Twitter Instagram
    Today News Journal
    Contact Us
    • Home
    • Trending
    • Business
    • Health
    • Technology
      • Automobile
      • Gadgets
      • Mobiles
      • Robotics
    • Lifestyle
      • Culture
    • Sports
    • Travel
    • Editorials
    • News
      • Politics
    Today News Journal
    Home » News » Why Lecanemab Sparks Cautious Hope in Alzheimer’s Research
    News

    Why Lecanemab Sparks Cautious Hope in Alzheimer’s Research

    James MartinBy James MartinJanuary 7, 2023No Comments6 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    Comment

    It was long ago — in 1906 — that German psychiatrist Alois Alzheimer first connected a case of dementia to abnormal deposits in the brain. Modern researchers have largely proceeded on the thesis that treatments for the disease named for him would need to clear away these aberrant clumps, consisting of a protein called amyloid, that clog patients’ brains. After many disappointing performances by amyloid-targeting drugs, including one controversially approved by US regulators in 2021, a treatment called lecanemab became the first to unambiguously slow the progression of Alzheimer’s disease in a large trial reported in late 2022. The results provided a rare burst of hope to the field of Alzheimer’s research. At the same time, the medicine, cleared by the FDA Jan. 6, has many limitations. 

    Jointly developed by Eisai Co. and Biogen Inc., lecanemab is a laboratory-made antibody designed to target a form of amyloid called protofibrils, which were implicated in the case of a Swedish family ravaged by early-onset Alzheimer’s. In an 18-month efficacy trial involving 1,800 patients with early Alzheimer’s, those who received lecanemab, which will be sold under the brand name Leqembi, saw a significant reduction in brain amyloid levels. More importantly, the drug slowed their cognitive and functional decline by 27% compared to a group that received a placebo.

    2. What is lecanemab’s availability?

    Based on the drug’s amyloid lowering ability, the FDA gave a greenlight for it using an accelerated approval process for drugs that treat serious conditions, fill an unmet need and perform in a way that predicts a benefit to patients without actually measuring that benefit. Full FDA approval isn’t likely to come before later this year. The US federal Medicare program for the elderly, which covers most people with Alzheimer’s, has indicated it won’t broadly cover amyloid-lowering drugs until they receive full approval based on clinical benefits, as opposed to accelerated approval based on amyloid lowering alone.

    3. Who is lecanemab for? 

    The drug has been tested on people in the early stages of the disease, in which symptoms include mild forgetfulness that often accompanies aging but also possibly problems concentrating. Most patients in the big lecanemab trial had mild cognitive impairment, while some had mild dementia. To qualify for the drug, people will likely need to be tested for signs of brain amyloid, present in more than two-thirds of Alzheimer’s patients and around half of 10 million more with mild cognitive impairment. A brain amyloid PET scan is one possibility but it can cost as much as $7,000. Medicare has restricted coverage of the scans, and most hospitals perform this test only occasionally. Spinal taps are another way to get tested, but they’re invasive and sometimes painful, so some patients shy away. A few blood tests available commercially in the US can provide an indication whether amyloid is present in the brain, but none are routinely covered by insurers or cleared by the FDA. Japan’s health ministry approved such a test, developed by Sysmex Corp and Eisai, in December. 

    4. What are the limitations of lecanemab?

    The slowing of cognitive decline seen in the trial was modest, and the drug does not stop disease progression. Lecanemab’s benefits come with side effects. In the trial, more than one in five people on the medicine experienced brain swelling or bleeding. Most cases weren’t symptomatic, though patients sometimes had headaches, visual disturbances and confusion, and five people developed large brain hemorrhages. Two people taking blood thinners died in the extension phase of the trial; Eisai says lecanemab wasn’t to blame. The drug is administered as an infusion every two weeks, which means patients must receive it at a health center. It’s likely to be expensive. Using earlier stage studies, Eisai researchers estimated the annual price might range from $9,000 to $35,000.

    5. Why was the approval of a different amyloid drug controversial?

    In June 2021, the FDA approved Aduhelm, another Alzheimer’s treatment from Biogen and Eisai, despite conflicting trial results. One big study showed no effect while another showed a small benefit in slowing cognitive decline; both trials were stopped early by Biogen, making the results hard to interpret. The agency cleared the drug against the advice of a panel of outside medical experts. Three members of the group resigned afterward, and Medicare heavily restricted payments for Aduhelm. The drug’s makers eventually stopped marketing it in the US. Congressional investigators in December concluded that the Aduhelm approval process was “rife with irregularities,” stating that the FDA collaborated excessively with Biogen while assessing the drug.

    6. Will lecanemab have competitors?

    Not many initially. The main potential competitor nearing approval is Eli Lilly & Co.’s donanemab. In a phase 2 trial reported in 2021, donanemab dramatically lowered brain amyloid and slowed cognitive and functional decline by 32% in people with early stage Alzheimer’s. The company has applied for accelerated approval in the US based on amyloid lowering. It is conducting a larger phase 3 trial that should report results this year; a positive outcome could lead to full approval. Another amyloid lowering antibody from Roche Holding AG called gantenerumab failed to slow cognitive decline in two large trials reported at a medical conference in November.

    7. What are the future paths for Alzheimer’s research?

    After the Aduhelm debacle, the lecanemab results strengthened the argument that researchers are on the right path in targeting amyloid. Still, it’s not yet clear why the lecanemab results were better than those from most amyloid-lowering medications. Some researchers suspect that a certain threshold of amyloid removal must be met before drugs show a benefit. But with the benefits limited even to those in the early stages of Alzheimer’s – possibly because damage to key brain areas is already extensive – some researchers are focused on getting ahead of the disease. Brain scan studies suggest that amyloid starts accumulating in the brain as long as two decades before someone has dementia. In massive final-stage trials underway at Eli Lilly Co. and Eisai Co., researchers plan to test amyloid-removing drugs on thousands of healthy adults. The hope is to stave off cognitive decline before it begins, or at least delay it. Meanwhile, researchers are also focused on other things that go awry in Alzheimer’s, including an increase in a second protein called tau, and brain inflammation that may lead to nerve cell death. Various companies are targeting both these processes with other drugs in testing, though there have been no breakthroughs so far.

    More stories like this are available on bloomberg.com



    Source link

    Related posts:

    1. Exclusive: Michael Keaton’s family reveal nephew’s tragic death from opioids
    2. DirecTV latest network to drop RT amid Russian invasion of Ukraine
    3. NASA SLS moon rocket readied for first launch as Artemis program begins
    4. UK strike calendar – service stoppages planned for January | Rail strikes
    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleThis Won’t Be the Last Breakdown in the House
    Next Article How Crypto’s Meltdown Changed the Regulatory Debate
    James Martin
    • Website

    Related Posts

    What does it mean to raise the U.S. debt ceiling? The fight, explained

    May 26, 2023

    Debt ceiling deal within sight as Biden and Republicans continue to negotiate | US politics

    May 26, 2023

    Politics should be taught in primary schools, Alastair Campbell says | Alastair Campbell

    May 25, 2023

    Australia news live: fears of further collapse after huge Sydney fire; NSW to consider ‘breach of trust’ fines in wake of PwC scandal | Australia news

    May 25, 2023

    Leave A Reply Cancel Reply

    Search
    Categories
    • Automobile
    • Business
    • Coronavirus
    • Culture
    • Editorials
    • Finance
    • Gadgets
    • Health
    • Lifestyle
    • Mobiles
    • Money
    • News
    • Politics
    • Sports
    • Technology
    • Travel
    • Trending
    • World
    Latest Posts

    Statue of Adam Goodes’s ‘iconic’ war cry unveiled by AFL club Sydney Swans | Adam Goodes

    May 26, 2023

    Hull KR talking points as old habits creep in but panic stations miles away

    May 26, 2023

    Kate Middleton citrine cocktail ring: Jewel shows ‘independence’

    May 26, 2023

    Recipe: Chef’s chicken chow mein is ‘just like a takeaway would do it’

    May 26, 2023
    • Facebook
    • Twitter
    Don't Miss

    Statue of Adam Goodes’s ‘iconic’ war cry unveiled by AFL club Sydney Swans | Adam Goodes

    By James MartinMay 26, 20230

    The Sydney Swans have unveiled a bronze sculpture of Indigenous superstar Adam Goodes out the…

    Hull KR talking points as old habits creep in but panic stations miles away

    May 26, 2023

    Kate Middleton citrine cocktail ring: Jewel shows ‘independence’

    May 26, 2023

    Recipe: Chef’s chicken chow mein is ‘just like a takeaway would do it’

    May 26, 2023
    • Facebook
    • Twitter
    About Us

    Hello friends, I am James Martin. Welcome to my blog todaynewsjournal.com. We are a team of experienced journalists who are passionate about delivering the latest news and current events to our readers. Our editorial team is dedicated to providing the most accurate and up-to-date information possible. We aim to be your go-to source for news and current events. Here on this site, You will get up to date information regarding all important categories like business ideas, health tips,... (Read More)

    Latest News

    Statue of Adam Goodes’s ‘iconic’ war cry unveiled by AFL club Sydney Swans | Adam Goodes

    May 26, 2023

    Hull KR talking points as old habits creep in but panic stations miles away

    May 26, 2023

    Kate Middleton citrine cocktail ring: Jewel shows ‘independence’

    May 26, 2023
    SIGN UP NEWSLETTER

    Join The Conversation sign up to receive emails for The Daily special tips general info.

      Facebook Twitter Instagram Pinterest
      • Home
      • Editorials
      • Get In Touch

      Copyright © 2021-2023 · Today News Journal Privacy Policy

      Type above and press Enter to search. Press Esc to cancel.

      We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
      Cookie SettingsAccept All
      Manage consent

      Privacy Overview

      This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
      Necessary
      Always Enabled
      Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
      CookieDurationDescription
      cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
      cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
      cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
      cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
      cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
      viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
      Functional
      Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
      Performance
      Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
      Analytics
      Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
      Advertisement
      Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
      Others
      Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
      SAVE & ACCEPT

      Sign In or Register

      Welcome Back!

      Login to your account below.

      Lost password?